Oragenics Partners With Receptor.AI To Expand AI-Driven Neurological Drug Discovery

Oragenics, Inc., a clinical-stage biotechnology company advancing brain-targeted therapeutics via proprietary intranasal delivery technology, announced a strategic collaboration with Receptor.AI, an artificial intelligence-driven drug profiling company. The partnership aims to accelerate discovery and development of an expanded portfolio of pharmaceutical candidates addressing neurological and psychiatric conditions.

"We're embracing cutting-edge technology with the goal of building a robust pipeline while maintaining capital efficiency," said Janet Huffman, Chief Executive Officer of Oragenics. "This partnership with Receptor.AI demonstrates our commitment to innovation at every level—from our proprietary intranasal delivery platform to the tools we use to identify promising therapeutic candidates. By leveraging AI to guide our preclinical work, we believe we can focus resources on the most promising opportunities and potentially accelerate our path to identifying new treatments for a wide range of neuropsychiatric conditions."

The collaboration marks a key milestone in Oragenics’ transformation from a single-asset company into a diversified neuroscience innovator. Through this partnership, Receptor.AI will leverage its advanced AI modeling platform to predict receptor binding profiles for novel compounds acquired by Oragenics in 2023. These insights will help streamline laboratory validation and guide the company’s expansion beyond its lead candidate, ONP-002, currently advancing toward Phase IIa trials for concussion.

''At Receptor.AI, we are committed to enabling partners like Oragenics with advanced AI-driven insights that streamline drug discovery and support efficient pipeline growth. This collaboration reflects the practical value of applying AI to early-stage development to guide resources toward the most promising therapeutic opportunities," said Dr. Alan Nafiiev, Chief Executive Officer of Receptor.AI.

Using AI-generated receptor predictions, Oragenics plans to identify therapeutic targets across Alzheimer’s disease, Parkinson’s disease, PTSD, opioid addiction, and anxiety disorders. The collaboration highlights Oragenics’ strategy to de-risk early-stage discovery, optimize R&D efficiency, and strengthen its position as a platform technology leader in intranasal neurological pharmaceuticals. With ONP-002 trial initiation expected in Q4 2025, this partnership sets the stage for a next-generation neuroscience pipeline.

"We believe our intranasal delivery platform has applications beyond concussion," added Janet Huffman. "By combining our delivery technology with AI-guided drug discovery, we're hoping to build a sustainable, multi-asset company that can address unmet needs across the neurological disease spectrum. This is about creating long-term value through smart science and strategic innovation."